Objective: To investigate anti-apoptogenic mechanism of transforming growth factor b1 (TGFb1) towards synovial cells. Methods: Isolated synovial cells, treated or not with TGFb1, were cultured in the presence or absence of anti-Fas IgM, proteasome inhibitor Z-Leu-Leu-Leu-aldehyde (LLL-CHO), etoposide, or C2-ceramide. After cultivation, apoptosis of synovial cells was examined by the presence of hypodiploid DNA + cells, the presence of terminal deoxy (d)-UTP nick end labelling + cells (TUNEL + cells), activation of caspases, and disruption of mitochondrial transmembrane potential (DYm). Results: Activation of caspase-9 and DYm was found in antiFas IgM treated synovial cells. The increment of both hypodiploid DNA + cells and TUNEL + cells accompanied by the activation of caspase-8 and caspase-3 was also determined in anti-Fas IgM treated synovial cells. These hallmarks for apoptosis induced by anti-Fas IgM were significantly suppressed in TGFb1 treated synovial cells. LLL-CHO, etoposide, and C2-ceramide also caused DYm, the increment of both hypodiploid DNA + cells and TUNEL + cells, and the activation of both Leu-Glu-His-Asp ase (LEHDase; caspase-9 like activity) and Asp-Glu-Val-Asp ase (DEVDase; caspase-3 like activity) in synovial cells. As determined in anti-Fas IgM treatment, TGFb1 significantly reduced apoptotic cell death of synovial cells induced by the above chemicals. Conclusions: The protective effect of TGFb1 for mitochondrial homoeostasis may be important in the anti-apoptogenic function of TGFb1 for synovial cells.
C ytokines and growth factors present in rheumatoid synovial tissues are important factors which regulate an apoptotic process of synovial cells. [1] [2] [3] [4] [5] Transforming growth factor b1 (TGFb1) is highly expressed in rheumatoid synovial tissues, 6 and found to possess an anti-apoptogenic effect for synovial cells; this was demonstrated by the experimental results showing that TGFb1 inhibits Fas mediated apoptosis as well as proteasome inhibitor induced apoptosis in cultured synovial cells. 2 3 TGFb1 not only suppresses Fas expression, but increases the expression of Bcl-2 and Bcl-xL in cultured synovial cells. 2 3 the latter finding implies that TGFb1 protects synovial cells from apoptogenic stimuli through a mitochondria dependent mechanism.
We show in this study that mitochondrial perturbation as well as both DNA fragmentation and the activation of caspases in cultured synovial cells, induced by several apoptogenic stimuli, are significantly suppressed by TGFb1 treatment, which may be closely associated with the antiapoptogenic function of TGFb1.
MATERIALS AND METHODS
Synovial cell culture Synovial cells were isolated from synovial tissues obtained from 18 patients with rheumatoid arthritis (RA) who met the American College of Rheumatology criteria for RA 7 at the time of orthopaedic surgery, as we previously described. [2] [3] [4] [5] In some experiments, synovial cells isolated from patients with osteoarthritis were also used in this study. The adherent synovial cells used in this study at third to fifth passages were less than 1% reactive with monoclonal antibodies, including CD3, CD68, CD20, and von Willebrand factor, which are defined as fibroblast-like synovial cells.
Induction of synovial cell apoptosis by several apoptogenic stimuli Synovial cells were cultured with or without recombinant human TGFb1 (5 ng/ml; R&D Systems Inc, Minneapolis, MN) for 48 hours in RPMI 1640 containing 2% bovine serum albumin. After incubation, apoptosis sensitivity in untreated or TGFb1 treated synovial cells was examined by further incubation with anti-Fas IgM (1 mg/ml for 12 hours; MBL, Nagoya, Japan), Z-Leu-Leu-Leu-aldehyde (LLL-CHO, 10 mM for 24 hours, Peptide Institute, Osaka, Japan), etoposide (50 mM for 24 hours; TopoGen, Inc, Columbus, Ohio), or C2-ceramide (50 mM for 24 hours; Sigma). Apoptosis of synovial cells was quantified by the presence of hypodiploid DNA + cells, the presence of terminal deoxy (d)-UTP nick end labelling + cells (TUNEL + cells), activation of caspases, and disruption of mitochondrial transmembrane potential (DYm) as previously described. 3 5 8 9 DNA fragmentation was estimated by the presence of hypodiploid DNA + cells and TUNEL + cells, determined by flow cytometry (Epics XL, Beckman Coulter, Hialeah, FL). Detection of hypodiploid DNA + cells was done by propidium iodide staining (100 mg/ml; Sigma Chemical Co, St Louis, MO), and TUNEL was examined by Mebstain Apoptosis Kit (MBL, Nagoya, Japan).
Activation of caspases in synovial cells was studied by western blot analysis, colorimetric protease assay and flow cytometry. Western blot analysis was done by Decrement of procaspase expression and/or the appearance of cleaved products indicate the activation of each caspase. 10 In addition to western blotting, increment of an enzymatic activity of Asp-Glu-Val-Asp ase (DEVDase: caspase-3 like activity), Ile-Glu-Thr-Asp ase (IETDase: caspase-8 like activity), and Leu-Glu-His-Asp ase (LEHDase: caspase-9 like activity) was used for detection of activation in each caspase.
Enzymatic activity of DEVDase (intracellular DEVDase + cells) was detected by flow cytometry (Epics XL) by the use of DEVD substrate (OncoImmunin, Inc, College Park, MD) as previously described. 8 Enzymatic activity of both IETDase and LEHDase was examined by colorimetric protease assay kit (MBL), and the activity of IETDase and LEHDase was evaluated by a spectrophotometer at an optical density of 405 nm (Multiskan JX, LABSYSTEMS, Tokyo, Japan), according to the manufacturer's protocol.
Expression of Bcl-2 (anti-Bcl-2; Dako Japan, Kyoto, Japan), Bcl-xL (anti-Bcl-xL; Trevigen, Gaithersburg, CA), and Bax (anti-Bax; Santa Cruz Biotechnology, Santa Cruz, CA) in synovial cells was studied by western blotting, and a relative expression ratio of Bcl-2 to Bax and of Bcl-xL to Bax was calculated by the software NIH Image (1.61) as follows: density of Bcl-2 or Bcl-xL/density of b-actin to density of Bax/
Mitochondrial perturbation in synovial cells was examined by DYm. 9 The cells were reacted with saturating amount of DiOC6 (3,39-dihexyloxacarbocyamine iodide, Fluoreszenztechnologie, Grottenhofstr, Austria) at 37˚C for 15 minutes, washed, and analysed by flow cytometry. In some experiments, synovial cells were cultured in the presence of Z-Val-Ala-Asp-CH 2 DCB (caspase inhibitor, 200 mM; Phoenix Pharmaceuticals, Inc, Mountain View, CA), and apoptosis of these cells was also examined.
Statistical analysis
Data were expressed as mean (SD) . Differences between groups were tested for statistical significance using the Student's t-test. A p value ,0.05 was considered significant.
RESULTS

Inhibition of Fas mediated mitochondrial perturbation in cultured synovial cells by TGFb1
Although we did not find the cleaved products of each caspase, activation of caspase-3/-8/-9 in synovial cells by antiFas IgM was strongly suggested by western blotting (fig 1) , which was confirmed by an enzymatic activity assay for DEVDase, IETDase, and LEHDase (table 1) . Mitochondrial perturbation with DNA fragmentation in synovial cells was also clearly induced by anti-Fas IgM (table 1) . Expression of procaspase-3/-8/-9 in synovial cells was not changed by TGFb1 (fig 1) , but TGFb1 treatment significantly suppressed DYm, activation of caspase-3/-8/-9, and DNA fragmentation of synovial cells induced by anti-Fas IgM (fig 1, table 1 ).
Effect of TGFb1 for synovial cell apoptosis induced by other apoptogenic stimuli
We next examined whether TGFb1 treatment protects mitochondrial perturbation induced by other apoptogenic stimuli. LLL-CHO, etoposide, and C2-ceramide, the chemicals triggering apoptosis in a mitochondria dependent fashion, [11] [12] [13] induced DYm with the presence of DNA fragmentation toward synovial cells (table 2) . Z-Val-Ala-Asp-CH 2 DCB did not inhibit DYm of synovial cells in the process (data not shown), which supported the importance of the mitochondrial pathway in synovial cell death induced by LLL-CHO, etoposide, and C2-ceramide. Activation of both LEHDase and DEVDase was also clearly found in synovial cells treated with the chemicals, and TGFb1 treatment significantly suppressed the above hallmarks for apoptosis (table 2). As we previously described, 3 
DISCUSSION
Our series of studies have indicated that the growth promoting activity of TGFb1 for synovial cells can, in part, be mediated by inhibition of synovial cell apoptosis. 2 3 As reported in other cell types, 14 15 activation of caspase-3/-8/-9 as well as DYm was found in anti-Fas monoclonal antibody treated synovial cells, whereas these hallmarks for apoptosis were markedly suppressed in TGFb1 treated synovial cells.
Mitochondrial dysfunction in synovial cells was also induced by LLL-CHO, etoposide, and C2-ceramide, leading to the activation of caspase-3/-9 and DNA fragmentation. TGFb1 treatment significantly suppressed apoptogenic activity of LLL-CHO, etoposide, and C2-ceramide. As we previously reported, 3 relative expression of Bcl-2 and Bcl-xL was increased by TGFb1, which may prevent the release of cytochrome c and apoptotic cell death of synovial cells induced by the above chemicals. TGFb1 mediated protection for the mitochondria may also be effective in Fas induced apoptosis in synovial cells.
Impaired apoptosis of synovial cells in rheumatoid synovial tissues is supposed to have an important role in the progression of synovial cell hyperplasia of patients with RA, but recent investigations have suggested its characteristic may not be an intrinsic property of rheumatoid synovial cells, but that the rheumatoid synovial microenviroment affects the sensitivity of synovial cell apoptosis. 1-5 12 One factor which may inhibit apoptosis of synovial cells is TGFb1, but rheumatoid synovial tissue contains a variety of cytokines and growth factors other than TGFb1, which also inhibit apoptotic cell death of synovial cells, including basic fibroblast growth factor and interleukin 1b. 1 4 The present data are obtained only under bovine serum albumin culture conditions, thus, the in vivo role of TGFb1 in rheumatoid synovial tissues remains obscure. Further investigations, including interactions between TGFb1 and other humoral factors, are necessary to clarify the in vivo role of TGFb1 in the regulation of apoptotic cell death of synovial cells of patients with RA. 
